WBB Securities analyst Stephen Brozak reiterated a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) today. The company’s shares opened today at $153.69, close to its 52-week high of $176.50.
According to TipRanks.com, Brozak is a 4-star analyst with an average return of 22.6% and a 56.0% success rate. Brozak covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Melinta Therapeutics Inc, and Cidara Therapeutics.
Currently, the analyst consensus on Sarepta Therapeutics is Strong Buy and the average price target is $164.07, representing a 6.8% upside.
In a report issued on June 15, BTIG also initiated coverage with a Buy rating on the stock with a $120 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $176.50 and a one-year low of $32.36. Currently, Sarepta Therapeutics has an average volume of 1.49M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.
Read More on SRPT:
